Cell-destructive activity in the serum of a tumor patient after infusion of alkyl lysophospholipid.

Sera collected from 1 tumor patient after a 12-hour infusion of 30-50 mg alkyl lysophospholipids (ALP)/kg induced a progressive destruction of human leukemia cells (HL60) in vitro. This cytotoxic serum activity correlated with the dose of ALP administered and was inhibited by the addition of a metabolizable lysophospholipid analogue. Human bone marrow cells and concanavalin A-stimulated lymphoblasts were affected to a much lesser degree, whereas cells of the erythroleukemia line K562 appeared to be relatively resistant. When cells were cultured in postinfusion sera, the cytotoxicity of ALP in vitro was enhanced as much as fifteenfold when compared with the cytotoxicity of ALP when the cells were cultured in normal sera. No change in either relative or absolute distribution of phospholipids in postinfusion sera could be detected.

Destruction of human solid tumors by alkyl lysophospholipids.

Alkyl lysophospholipids (ALP) are synthetic analogs of the naturally occurring 2-lysophosphatidylcholine. The effect of ALP on the proliferation of 22 different gynecologic malignant tumors in humans was studied in vitro. ALP caused progressive death of tumor cells over 24-96 hours. In addition, tumor specimens from the tested human tumors were xenotransplanted into NMRI nude mice. ALP induced a highly significant retardation of the in vivo growing human tumors. Neither oral nor iv administration of these compounds caused any recognizable side effects.

Inhibition by alkyl-lysophospholipids of tritiated thymidine uptake in cells of human malignant urologic tumors.

Alkyl-lysophospholipids (ALP) inhibited the uptake of [3H]thymidine by cells from a variety of human urologic tumors in vitro. Cells of prostate carcinomas, a seminoma, various bladder carcinomas and teratocarcinomas showed proliferation rates that were 10% of those of the controls when incubated with some ALP for longer than 24 hours. Concentrations as low as 1 microgram ALP/ml medium (10(6) tumor cells) were effective. Antitumor action increased after incubation for 2-5 days. Morphologic studies showed tumor cell death after incubation periods of this length. Equivalent concentrations of conventional cytostatic drugs used in anticancer chemotherapy protocols did not cause greater inhibition of [3H]thymidine uptake by tumor cells in vitro. Human embryonic fibroblasts were not sensitive to ALP, whereas cytostatic drugs completely inhibited their proliferation at comparable doses.

Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine.

Human alveolar macrophages as well as macrophages derived from Teflon culture of blood-borne monocytes were incubated with synthetic analogues of 2-lysophosphatidylcholine and then tested for their cytotoxic capacity against an allogeneic lymphoma cell line. Metabolic, rather stable analogues enhanced macrophage cytotoxicity significantly. This phenomenon was shown both in a growth-inhibition assay as well as in the 51Cr release assay. Macrophage activation was dose- and time-dependent and was potentiated at temperatures above 37 degrees C. Incubation of the macrophages with the active compounds induced characteristic changes in cell morphology as revealed by scanning electron microscopy.

Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids.

Alkyl-lysophospholipids inhibit the growth of Meth A sarcoma cells in vitro. In contrast, murine bone marrow macrophages are not sensitive to the destructive effect of these substances. Since alkyl-lysophospholipids are antimetabolites in the synthesis of 3-sn-phosphatidylcholine, tumor cell destruction can be correlated with the disturbance of this metabolism. A decreased synthesis of 3-sn-phosphatidylcholine is accompanied by an increased degradation of cellular 3-sn-phosphatidylcholine in the presence of alkyl-lysophospholipids. As a consequence, endogeneously formed lysophospholipid accumulates, although the lysophospholipase is found to be stimulated. This accumulation of endogeneous lysophospholipids might be due to the fact that a high percentage of these compounds contain an alkyl bond which cannot be split by a lysophospholipase. On the other hand, the reacylation of the formed lysophospholipids is partially blocked as the lysophosphatidylcholine acyltransferase is inhibited by the added alkyllysophospholipids. An accumulation of potentially cytotoxic lysophospholipids in tumor cells might be an additional factor in the tumor cell destruction by alkyl-lysophospholipids.

Ether phospholipids as inhibitors of the arachidonoyl-CoA: 1-acyl-sn-glycero-3-phosphocholine acyltransferase in macrophages.

1-Alkylglycerophosphatide analogs which are known to activate macrophages to enhanced tumor cytotoxicity are structurally closely related to 1-acyl-sn-glycero-3-phosphocholine. In this study we have examined the influence of some of these compounds and of platelet-activating factor (PAF-acether, 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine) on the arachidonoyl-CoA: 1-acyl-sn-glycero-3-phosphocholine acyltransferase (EC 2.3.1.23) in homogenate of bone-marrow-derived murine macrophages. This enzyme is suggested to be involved in the control of the availability of the icosanoid precursor, arachidonic acid. Kinetic experiments revealed apparent Km and V values for 1-palmitoyl-sn-glycero-3-phosphocholine of 6.0 microM and 16.10 nmol/mg protein per min, respectively. When the 1-palmitoyl-sn-glycero-3-phosphocholine concentration was equal to Km, the enzyme was dose-dependently inhibited by 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine with a 50% inhibition at 30 microM. The kinetic parameters in the presence of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (K'm = 10.0 microM, V' = 11.40 nmol X mg-1 X min-1) suggest that this alkyl phospholipid is a mixed-type inhibitor. All other alkyl analogs tested (1-O-methyl-2-O-octadecyl-rac-glycerol-3-phosphocholine, racemic PAF-acether, L-PAF-acether, D-1-O-hexadecyl-sn-glycero-3-phosphocholine, 1-O-octadecyl-rac-glycero-3-phosphocholine) inhibited the enzyme to various degrees. Arachidonic acid transfer to the 1-alkylglycerophosphatide analogs themselves could be ruled out under the assay conditions used. Therefore, we conclude that the arachidonoyl-CoA: 1-acyl-sn-glycero-3-phosphocholine acyltransferase can be inhibited by synthetic and naturally occurring ether phospholipids in homogenate of bone-marrow-derived murine macrophages.

Influence of platelet activating factor and a nonmetabolizable analogue on superoxide production by bone marrow derived macrophages.

Serum-free cultured macrophages could be stimulated for lucigenin-dependent chemiluminescence by platelet activating factor (PAF) and phorbol myristate acetate (PMA). Stimulation with PMA resulted in a desensitization against PAF, whereas prestimulation with PAF had no influence on a following response caused by PMA. The PAF analogue, 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (Et-18-OCH3), did not induce chemiluminescence by itself and desensitized the cells against PAF, like substimulating concentrations of PAF. PAF and PMA responsiveness was rapidly modulated in a similar manner during adherence of the cells to polystyrene tubes. At higher concentrations, Et-18-OCH3 as well as lysophosphatidylcholines potentiated PMA-induced chemiluminescence. The PAF analogue was most effective. Although PMA-induced chemiluminescence was stimulated at least 5-fold by Et-18-OCH3, this compound increased the PMA-induced activation of protein kinase C only 1.39-fold. The priming effect of Et-18-OCH3 was not reduced in the absence of extracellular Ca2+ and after cell membrane depolarisation.

Temperature dependence of leukemic cell destruction by alkyl-lysophospholipids (NSC 324368).

Alkyl-analogs (ALP) of 2-lysophosphatidylcholine induce a progressive destruction of neoplastic cells by interfering with the continuous turnover of membrane phospholipids. Using leukemic blast cells from patients with acute forms of leukemia the effect of temperature was evaluated. It was found that temperature strongly influences the cytotoxic activity of ALP. High temperatures potentiate whereas a slight decrease in temperature reduces leukemic cell destruction by ALP. At temperatures below 30 degrees C even high doses of ALP will not destroy these tumor cells. Furthermore, cell destruction initiated at 37 degrees C can be abolished by lowering the incubation temperature to 25 degrees C. These biological data have been confirmed by biochemical studies, showing a temperature dependence of ALP adsorption not accompanied by a corresponding increase of alkyl-cleavage enzyme activity. The rate of membrane phospholipid turnover seems to be essential for temperature dependent ALP induced cell destruction.

Macrophage mediated tumor cell destruction measured by an alkaline phosphatase assay.

A new assay to measure the cytotoxic or growth-inhibitory activity of macrophages against tumor cells is described. The method is based on the fact that, in contrast to macrophages, natural killer cells or cytotoxic lymphocytes, a variety of tumor cells have a very high content of alkaline phosphatase. The strong linearity between tumor cell number and alkaline phosphatase activity in the cultures permits evaluation of macrophage function with standard ELISA equipment.

Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.

The R- and S-enantiomers of 2-[[hydroxyl[[2-[(octadecyloxy) methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N,N,N,- trimethylethylaminium hydroxide salt (SRI 62-834) have been evaluated in several assays to determine potential antitumor activity. The S-enantiomer showed slightly greater cytotoxic activity than the R- or RS-forms against several murine tumor cell lines. In the mouse Meth A fibrosarcoma model, the S-enantiomer was ca. 4 times more effective than the R-isomer in controlling size of tumor growth and increasing the number of survivors.

Antitumor activity of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinolines.

A series of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinolines previously reported to be platelet activating factor (PAF) receptor antagonists were evaluated for potential antitumor activity. Several compounds, such as the 5-(4'-tert-butylphenyl) (65), 5-[4'-(trimethylsilyl)phenyl] (69), and 5-(4'-cyclohexylphenyl) (71) analogs showed very good cytotoxicity against several tumor cell lines. 5-[4'-(Piperidinomethyl)phenyl]-2,3-dihydroimidazo[2,1- a]isoquinoline (SDZ 62-434, 53) was more effective on a milligram per kilogram basis than the clinical cytostatic agent edelfosine (1) in increasing survivors and decreasing tumor volume in the oral mouse Meth A fibrosarcoma assay. It was selected for further development and is currently in phase I clinical trials in cancer patients.

Age-related changes in interleukin production in BALB/cNNia and SJL/J mice and their modification after administration of foreign macromolecules.

In vitro production of Interleukin-2, -3, -4 and -10 by activated lymphocytes of BALB/cNNia and SJL/J was studied. While IL-2 production in BALB/c mice remains constant throughout the life span of the animals (8-113 weeks), an increase in production from stimulated SJL cells was seen. Age-related increases in IL-3 and IL-4 production occur between young and middle age (8-60 weeks) in both strains. Some organ differences in quantity of lymphokine produced were seen; the direction of age-related changes was the same for lymphocytes of spleen and MLN. The exceptional feature of BALB/cNNia was the relative stabilization of the levels of interleukin production, as animals approach old age. BALB/cNNia and SJL, which are at the two opposite extremes of lifespan, differ also in their response to molecular interventions: in BALB/cNNia fetal sheep liver extract and hemocyanin increase the output of interleukins. This is in striking contrast to the effects observed in older SJL mice in which the extract reduced the output of IL-3 and IL-4 by old animals, whereas hemocyanin increased the output of IL-2 and IL-3 at all ages tested.

Alkyl-lysophospholipid induced suppression of human lymphocyte response to mitogens and selective killing of lymphoblasts.

Alkyl-analogs of 2-lysophosphatidylcholine have been found to inhibit the response of human peripheral blood lymphocytes to mitogens and allogeneic cells. Furthermore, these compounds kill selectively transformed lymphocytes in vitro while resting lymphocytes are not affected in their viability. The increased incorporation of fatty acids into cellular phospholipids during lymphocyte stimulation has been shown to be inhibited by these alkyl-lysophospholipids. Both resting and transformed lymphocytes could be shown to have an 1-0-alkyl-cleavage enzyme. Thus, selective cytotoxicity for lymphoblasts is not due to principal differences in the metabolism of alkyl-lysophospholipids as we have demonstrated to be the case between normal and leukemic cells, but is most likely due to the interference of these substances with the enhanced turnover of cellular phospholipids in stimulated lymphocytes.

Alkyl-lysophospholipids inhibit the growth of hypernephroid carcinomas in vitro.

Synthetic alkyl-lysophospholipids (ALPs) inhibit the proliferation of human hypernephromas in vitro. Cells of ten different tumors were incubated with 4 ALPs for periods of more than 24h. Eight of ten cell lines showed proliferation rates below 1% of the controls after cultivation. One microgram of ALPs per 10(6) tumor cells was effective, in some experiments a dose response relation was found for even lower concentrations. Equivalent concentrations of cytostatic drugs did not show reproducible higher antitumor effects in vitro. In two of the tested cell lines ALPs did not show any reproducible tumor growth inhibition, whereas at least some of the cytostatic drugs revealed slight cytostatis.

Effect of a lysolecithin analogue on nonspecific resistance to infection of mice.

The effect of racemic 1-octadecyl-2-methoxy-sn-glycero-3 phosphorylcholine (ET-18-OCH3) on the nonspecific resistance of mice to infection with Salmonella typhimurium was investigated. Two S. typhimurium strains with different virulence were studied and no effect was observed in either case at concentrations of ET-18-OCH3 up to 100 micrograms/mouse. However, a concentration of 500 micrograms/mouse caused decreased resistance to S. typhimurium, correlating with a depression of carbon clearance. Treatment of macrophages with ET-18-OCH3 in vitro inhibited phagosome-lysosome fusion, but had no effect on zymosan-induced luminol-dependent chemiluminescence. The relationship between the adjuvant and nonspecific anti-infectious activity of ET-18-OCH3 and other compounds is discussed.

Anti-tumor action of alkyl-lysophospholipids (Review).

Alkyl-lysophospholipids (ALP) are synthetic analogs of the naturally occurring 2-lysophosphatidylcholine. Some of these compounds show significant prophylactic and therapeutic activity against the growth of various allogeneic and syngeneic mouse tumors. Furthermore, they reproducibly inhibit the development of metastases of Lewis lung carcinoma in syngeneic mice. The antitumor action of ALP is mediated by an induction of cytotoxic macrophages and by a direct, selective destruction of neoplastic cells. Among other possible mechanisms, both phenomena might be based on a disturbance of the phospholipid metabolism in the tumor cell membrane, due to a lack of a 1-0-alkyl cleavage enzyme. In preliminary studies, ALP revealed only limited toxicity.

Growth inhibition of malignant hypernephroma cells by autologous lysophospholipid incubated macrophages obtained by a new method.

In order to obtain pure human macrophages, mononuclear cells from peripheral blood were cultured on teflon membranes and the non-adherent lymphocytes removed. After 24 hours, all remaining adherent cells were detached from the membranes with 100% viability. They showed all the morphological and cytochemical characteristics of human monocytes. Within 10 days of cultivation they differentiated into monolayers of pure macrophages. Untreated macrophages of this origin showed only limited cytostatic effects on autologous hypernephroma cells in vitro. After preincubation with different alkyl-lysophospholipids they revealed a tumor growth inhibition capability of up to 90%.

Studies on various parameters influencing leukemic cell destruction by alkyl-lysophospholipids.

Critical parameters of alkyl-lysophospholipid (ALP) induced destruction of freshly isolated human leukemic cells have been evaluated. The destructive activity of ALP is shown to be competitively inhibited by metabolizable lysophospholipids added to the cultures. It has also been found that destruction depends on the amount of serum present. Temperature and Ph strongly influence the cytotoxic activity of ALP. A slight decrease in temperature causes a reduction in cell death, whereas a temperature increase results in a marked potentiation. At low pH ALP cytotoxicity is inhibited. Incubation of cells with combinations of ALP and other cytotoxic drugs revealed a striking cytotoxic synergism with vinca-alkaloids, whereas corticosteroids retarded ALP induced cell destruction.

Increased membrane permeability for an antitumoral alkyl lysophospholipid in sensitive tumor cells.

We have investigated cellular sensitivity to the antitumoral alkyl lysophospholipid (ALP) 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3) in vitro. The permeation of this lipid into the cell was not influenced by metabolic inhibitors of ATP biosynthesis. ET-18-OCH3 uptake was not saturable within sublytic concentrations, but could be inhibited in part by cytochalasin B (CB) and dipyridamole. The activation energy of the CB-sensitive uptake process was increased up to threefold compared to CB-insensitive uptake. ET-18-OCH3 influx and equilibrium binding of ET-18-OCH3 were decreased in a fibrosarcoma cell variant (MethA) selected for ET-18-OCH3 resistance. The resistant MethA cells were also less sensitive to cytolysis by lysophosphatidylcholine and other ALP. After 72 hr, the resistant MethA cells had metabolized only 11.8% more of the absorbed ET-18-OCH3 than sensitive MethA cells. However, they tolerated at least a 30-fold concentration of this ALP. The uptake mechanism, which could be inhibited by CB, was less active in resistant MethA cells and several other ALP-resistant cell lines. The concentration of CB, required for maximal uptake inhibition, was increased more than four times in the ALP-sensitive tumor cell lines. CB-specific ET-18-OCH3 uptake was also enhanced after virus transformation of 3T3 fibroblasts by SV 40. Dipyridamole retarded the ET-18-OCH3-mediated cell destruction.

Antitumor activity of Ilmofosine (BM 41.440) in the 3Lewis-lung carcinoma model.

Ilmofosine (1-hexadecylthio-2-methoxymethyl-1,3-propanediol-phosphocholine, BM 41.440) is a thioether phospholipid with cytostatic/cytotoxic properties. The antineoplastic activity of this compound was investigated in vivo in the 3Lewis-lung carcinoma system. 3Lewis lung tumor-bearing C57Bl/6 mice were treated with 0.625 to 40 mg Ilmofosine/kg per day p.o. either from days 1 to 9 or from days 11 to 28 after intrafoot-pad tumor cell inoculation. Ilmofosine caused a significant dose-related response on tumor growth and metastases, expressed in terms of tumor diameter, tumor weight, survival time and number of metastases-free animals as compared to sham-treated and positive (cyclophosphamide) controls. The results suggest that direct cytostatic/cytotoxic effects, rather than immune-modulatory mechanisms, preferentially contribute to the antitumor activity of Ilmofosine in vivo.